European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS

To develop 3D bioPRINTed osteoinductive constructs that deliver CHEMOtherapeutics within large bone defects that are surgically created when removing bone tumours.

Descripción del proyecto

Estructuras para la administración localizada de fármacos en el osteosarcoma

El osteosarcoma es una neoplasia maligna que se origina en los osteoblastos y, por lo general, aparece en personas jóvenes. Aunque la tasa de supervivencia tras la resección del tumor y la quimioterapia complementaria es del 60 %, una tercera parte de los enfermos sufre una recaída. El proyecto PRINT-CHEMO, financiado con fondos europeos, se propone desarrollar un tratamiento basado en nanopartículas que emplea el miR-29b, un conocido supresor tumoral y promotor de la diferenciación de osteoblastos, para regenerar el hueso, así como quimioterápicos. Este tratamiento innovador se administrará de forma localizada, lo que permitirá solucionar los efectos secundarios relacionados con la administración sistémica de dosis de fármacos elevadas. Es más, los investigadores del proyecto quieren analizar el potencial de la quimioterapia a la hora de prevenir la metástasis pulmonar y proporcionar al hueso dañado los estímulos regenerativos necesarios sin inducir la recidiva del tumor.

Objetivo

Osteosarcoma is the most commonly diagnosed bone tumour with most of these cases being in children and adolescents. Each year over 4,000 new cases of osteosarcoma are diagnosed in the United States. Osteosarcoma predominantly initiates in the metaphysis of long bones, such as the distal femur, proximal tibia and proximal humerus. Over 50% of these tumours are relatively resistant to radiation therapy, due to the molecular aberration of the tumour. The current gold standard for treatment is tumour resection and adjuvant chemotherapy, with a 5-year survival rate of 61.6% in patients aged 0-24 years old. Approximately one-third of patients diagnosed with osteosarcoma are expected to have a relapse, with only 15% of these patients surviving the disease a second time. Therefore, due to the young age of initial diagnosis, the management of this disease is a challenging and costly exercise, which has a significant socioeconomic cost, estimated to be €14.7 billion in Europe and $45 billion in the USA in the last 18 years. While significant progress has been made in trying to understand the intra-tumour heterogeneity and the evolutionary pattern of a subset of clones within the tumour, thus far, no major changes in treatment and outcome have been achieved. The hypothesis of PRINT-CHEMO is that localised delivery of self-assembled dendritic nanoparticles used as a first wave of treatment to deliver miR-194, a tumour suppressive gene, to the cells along with the delivery of nanoparticles loaded with chemotherapeutics would lead to higher survival rates and less side effects than systemic delivery of a higher dose of drug. Furthermore, PRINT-CHEMO not only aims to treat the diseased tissue but using 3D printing provide the necessary cues to allow for the body to regenerate the damaged bone caused due to tumour resection.

Coordinador

THE PROVOST, FELLOWS, FOUNDATION SCHOLARS & THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY & UNDIVIDED TRINITY OF QUEEN ELIZABETH NEAR DUBLIN
Aportación neta de la UEn
€ 257 561,28
Dirección
COLLEGE GREEN TRINITY COLLEGE
D02 CX56 DUBLIN 2
Irlanda

Ver en el mapa

Región
Ireland Eastern and Midland Dublin
Tipo de actividad
Higher or Secondary Education Establishments
Enlaces
Coste total
€ 257 561,28

Socios (1)